PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1799615
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1799615
Global Antimicrobial Resistance Surveillance Market Size, by Solution (Kits, System, Surveillance Software, Service), Application, End User and Regional Forecasts 2025-2035
Valued at approximately USD 6.36 billion in 2024, the Global Antimicrobial Resistance (AMR) Surveillance Market is poised to expand at a CAGR of 5.60% between 2025 and 2035, propelled by escalating global health concerns over the spread of drug-resistant pathogens. AMR surveillance has become a critical linchpin in the fight against emerging infectious diseases, enabling healthcare providers and policymakers to track resistance patterns, implement targeted interventions, and adapt treatment protocols effectively. The rising prevalence of hospital-acquired infections, combined with the steady increase in multi-drug resistant bacteria, is pushing governments, healthcare systems, and research bodies to invest heavily in robust surveillance infrastructure. This market's growth is further reinforced by international health mandates, technological innovations in molecular diagnostics, and a concerted push toward integrating surveillance data across borders for more rapid and precise response strategies.
The momentum is being fueled by the heightened recognition that real-time, data-driven insights can substantially mitigate the impact of antimicrobial resistance. Healthcare organizations and public health bodies are accelerating adoption of sophisticated software platforms, rapid diagnostic kits, and advanced surveillance systems to pinpoint resistance trends with greater accuracy. According to WHO projections, AMR could cause millions of deaths annually by mid-century if unchecked, underlining the urgency for expansive surveillance networks. Furthermore, integration of artificial intelligence and cloud-based analytics into AMR tracking is creating unprecedented opportunities to streamline data collection, automate reporting, and strengthen cross-sectoral collaboration. However, despite its vital role, the market faces constraints in the form of limited funding in low-resource settings, uneven laboratory capacities, and the challenges of harmonizing global data standards.
From a regional perspective, North America currently commands a dominant position in the AMR surveillance market, benefiting from its well-developed healthcare infrastructure, significant R&D investment, and stringent public health regulations that mandate systematic resistance monitoring. Europe follows closely, with robust surveillance programs like EARS-Net driving collaborative data-sharing efforts across member states. Meanwhile, Asia Pacific is projected to register the fastest growth over the forecast period, spurred by the escalating burden of infectious diseases in densely populated countries such as India and China, coupled with rising governmental and private-sector investments in healthcare IT. Latin America and the Middle East & Africa are gradually strengthening their surveillance networks, although infrastructural and funding gaps remain hurdles to fully realizing market potential.
Major market players included in this report are:
- bioMerieux SA
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Becton, Dickinson and Company
- Abbott Laboratories
- Danaher Corporation
- Siemens Healthineers AG
- Bruker Corporation
- Qiagen N.V.
- Illumina, Inc.
- OPKO Health, Inc.
- Hologic, Inc.
- Cepheid (A Danaher Company)
- Luminex Corporation
- Meridian Bioscience, Inc.
Global Antimicrobial Resistance Surveillance Market Report Scope:
- Historical Data - 2023, 2024
- Base Year for Estimation - 2024
- Forecast period - 2025-2035
- Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:
By Solution:
- Kits
- System
- Surveillance Software
- Service
By Application:
- Clinical Diagnostics
- Public Health Surveillance
By End User:
- Hospitals
- Clinics
- Academic
- Research Institutes
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2025 to 2035.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Antimicrobial Resistance Surveillance Market Report Scope & Methodology
- 1.1. Research Objective
- 1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
- 1.3. Research Attributes
- 1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
- 1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study
Chapter 2. Executive Summary
- 2.1. CEO/CXO Standpoint
- 2.2. Strategic Insights
- 2.3. ESG Analysis
- 2.4. Key Findings
Chapter 3. Global Antimicrobial Resistance Surveillance Market Forces Analysis
- 3.1. Market Forces Shaping The Global Antimicrobial Resistance Surveillance Market (2024-2035)
- 3.2. Drivers
- 3.2.1. Rising prevalence of hospital-acquired infections and multi-drug resistant pathogens
- 3.2.2. Technological advancements in molecular diagnostics and surveillance platforms
- 3.3. Restraints
- 3.3.1. Limited funding and infrastructure in low-resource settings
- 3.3.2. Challenges in global data standardization and harmonization
- 3.4. Opportunities
- 3.4.1. Integration of artificial intelligence and cloud analytics in AMR tracking
- 3.4.2. Growing governmental and international health mandates for resistance monitoring
Chapter 4. Global Antimicrobial Resistance Surveillance Industry Analysis
- 4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Forecast Model (2024-2035)
- 4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
- 4.4. Top Investment Opportunities
- 4.5. Top Winning Strategies (2025)
- 4.6. Market Share Analysis (2024-2025)
- 4.7. Global Pricing Analysis And Trends 2025
- 4.8. Analyst Recommendation & Conclusion
Chapter 5. Global Antimicrobial Resistance Surveillance Market Size & Forecasts by Solution 2025-2035
- 5.1. Market Overview
- 5.2. Global Antimicrobial Resistance Surveillance Market Performance - Potential Analysis (2025)
- 5.3. Kits
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
- 5.4. System
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035
- 5.5. Surveillance Software
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035
- 5.6. Service
- 5.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.6.2. Market size analysis, by region, 2025-2035
Chapter 6. Global Antimicrobial Resistance Surveillance Market Size & Forecasts by Application 2025-2035
- 6.1. Market Overview
- 6.2. Global Antimicrobial Resistance Surveillance Market Performance - Potential Analysis (2025)
- 6.3. Clinical Diagnostics
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
- 6.4. Public Health Surveillance
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
Chapter 7. Global Antimicrobial Resistance Surveillance Market Size & Forecasts by End User 2025-2035
- 7.1. Market Overview
- 7.2. Global Antimicrobial Resistance Surveillance Market Performance - Potential Analysis (2025)
- 7.3. Hospitals
- 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.3.2. Market size analysis, by region, 2025-2035
- 7.4. Clinics
- 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.4.2. Market size analysis, by region, 2025-2035
- 7.5. Academic
- 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.5.2. Market size analysis, by region, 2025-2035
- 7.6. Research Institutes
- 7.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 7.6.2. Market size analysis, by region, 2025-2035
Chapter 8. Global Antimicrobial Resistance Surveillance Market Size & Forecasts by Region 2025-2035
- 8.1. Global Antimicrobial Resistance Surveillance Market, Regional Market Snapshot
- 8.2. Top Leading & Emerging Countries
- 8.3. North America Antimicrobial Resistance Surveillance Market
- 8.3.1. U.S. Market
- 8.3.1.1. Solution breakdown size & forecasts, 2025-2035
- 8.3.1.2. Application breakdown size & forecasts, 2025-2035
- 8.3.1.3. End User breakdown size & forecasts, 2025-2035
- 8.3.2. Canada Market
- 8.3.2.1. Solution breakdown size & forecasts, 2025-2035
- 8.3.2.2. Application breakdown size & forecasts, 2025-2035
- 8.3.2.3. End User breakdown size & forecasts, 2025-2035
- 8.3.1. U.S. Market
- 8.4. Europe Antimicrobial Resistance Surveillance Market
- 8.4.1. UK Market
- 8.4.1.1. Solution breakdown size & forecasts, 2025-2035
- 8.4.1.2. Application breakdown size & forecasts, 2025-2035
- 8.4.1.3. End User breakdown size & forecasts, 2025-2035
- 8.4.2. Germany Market
- 8.4.2.1. Solution breakdown size & forecasts, 2025-2035
- 8.4.2.2. Application breakdown size & forecasts, 2025-2035
- 8.4.2.3. End User breakdown size & forecasts, 2025-2035
- 8.4.3. France Market
- 8.4.3.1. Solution breakdown size & forecasts, 2025-2035
- 8.4.3.2. Application breakdown size & forecasts, 2025-2035
- 8.4.3.3. End User breakdown size & forecasts, 2025-2035
- 8.4.4. Spain Market
- 8.4.4.1. Solution breakdown size & forecasts, 2025-2035
- 8.4.4.2. Application breakdown size & forecasts, 2025-2035
- 8.4.4.3. End User breakdown size & forecasts, 2025-2035
- 8.4.5. Italy Market
- 8.4.5.1. Solution breakdown size & forecasts, 2025-2035
- 8.4.5.2. Application breakdown size & forecasts, 2025-2035
- 8.4.5.3. End User breakdown size & forecasts, 2025-2035
- 8.4.6. Rest of Europe Market
- 8.4.6.1. Solution breakdown size & forecasts, 2025-2035
- 8.4.6.2. Application breakdown size & forecasts, 2025-2035
- 8.4.6.3. End User breakdown size & forecasts, 2025-2035
- 8.4.1. UK Market
- 8.5. Asia Pacific Antimicrobial Resistance Surveillance Market
- 8.5.1. China Market
- 8.5.1.1. Solution breakdown size & forecasts, 2025-2035
- 8.5.1.2. Application breakdown size & forecasts, 2025-2035
- 8.5.1.3. End User breakdown size & forecasts, 2025-2035
- 8.5.2. India Market
- 8.5.2.1. Solution breakdown size & forecasts, 2025-2035
- 8.5.2.2. Application breakdown size & forecasts, 2025-2035
- 8.5.2.3. End User breakdown size & forecasts, 2025-2035
- 8.5.3. Japan Market
- 8.5.3.1. Solution breakdown size & forecasts, 2025-2035
- 8.5.3.2. Application breakdown size & forecasts, 2025-2035
- 8.5.3.3. End User breakdown size & forecasts, 2025-2035
- 8.5.4. Australia Market
- 8.5.4.1. Solution breakdown size & forecasts, 2025-2035
- 8.5.4.2. Application breakdown size & forecasts, 2025-2035
- 8.5.4.3. End User breakdown size & forecasts, 2025-2035
- 8.5.5. South Korea Market
- 8.5.5.1. Solution breakdown size & forecasts, 2025-2035
- 8.5.5.2. Application breakdown size & forecasts, 2025-2035
- 8.5.5.3. End User breakdown size & forecasts, 2025-2035
- 8.5.6. Rest of APAC Market
- 8.5.6.1. Solution breakdown size & forecasts, 2025-2035
- 8.5.6.2. Application breakdown size & forecasts, 2025-2035
- 8.5.6.3. End User breakdown size & forecasts, 2025-2035
- 8.5.1. China Market
- 8.6. Latin America Antimicrobial Resistance Surveillance Market
- 8.6.1. Brazil Market
- 8.6.1.1. Solution breakdown size & forecasts, 2025-2035
- 8.6.1.2. Application breakdown size & forecasts, 2025-2035
- 8.6.1.3. End User breakdown size & forecasts, 2025-2035
- 8.6.2. Mexico Market
- 8.6.2.1. Solution breakdown size & forecasts, 2025-2035
- 8.6.2.2. Application breakdown size & forecasts, 2025-2035
- 8.6.2.3. End User breakdown size & forecasts, 2025-2035
- 8.6.1. Brazil Market
- 8.7. Middle East and Africa Antimicrobial Resistance Surveillance Market
- 8.7.1. UAE Market
- 8.7.1.1. Solution breakdown size & forecasts, 2025-2035
- 8.7.1.2. Application breakdown size & forecasts, 2025-2035
- 8.7.1.3. End User breakdown size & forecasts, 2025-2035
- 8.7.2. Saudi Arabia (KSA) Market
- 8.7.2.1. Solution breakdown size & forecasts, 2025-2035
- 8.7.2.2. Application breakdown size & forecasts, 2025-2035
- 8.7.2.3. End User breakdown size & forecasts, 2025-2035
- 8.7.3. South Africa Market
- 8.7.3.1. Solution breakdown size & forecasts, 2025-2035
- 8.7.3.2. Application breakdown size & forecasts, 2025-2035
- 8.7.3.3. End User breakdown size & forecasts, 2025-2035
- 8.7.1. UAE Market
Chapter 9. Competitive Intelligence
- 9.1. Top Market Strategies
- 9.2. bioMerieux SA
- 9.2.1. Company Overview
- 9.2.2. Key Executives
- 9.2.3. Company Snapshot
- 9.2.4. Financial Performance (Subject to Data Availability)
- 9.2.5. Product/Services Port
- 9.2.6. Recent Development
- 9.2.7. Market Strategies
- 9.2.8. SWOT Analysis
- 9.3. F. Hoffmann-La Roche Ltd.
- 9.4. Thermo Fisher Scientific Inc.
- 9.5. Becton, Dickinson and Company
- 9.6. Abbott Laboratories
- 9.7. Danaher Corporation
- 9.8. Siemens Healthineers AG
- 9.9. Bruker Corporation
- 9.10. Qiagen N.V.
- 9.11. Illumina, Inc.
- 9.12. OPKO Health, Inc.
- 9.13. Hologic, Inc.
- 9.14. Cepheid (A Danaher Company)
- 9.15. Luminex Corporation
- 9.16. Meridian Bioscience, Inc.
